Title
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy
UMMS Affiliation
Department of Molecular, Cell and Cancer Biology; Department of Biochemistry and Molecular Pharmacology; Schiffer Lab
Publication Date
2017-10-31
Document Type
Article
Disciplines
Biochemistry | Genetics and Genomics | Medicinal Chemistry and Pharmaceutics | Medicinal-Pharmaceutical Chemistry | Molecular Biology
Abstract
Developing tools to accurately predict the clinical prevalence of drug-resistant mutations is a key step toward generating more effective therapeutics. Here we describe a high-throughput CRISPR-Cas9-based saturated mutagenesis approach to generate comprehensive libraries of point mutations at a defined genomic location and systematically study their effect on cell growth. As proof of concept, we mutagenized a selected region within the leukemic oncogene BCR-ABL1 Using bulk competitions with a deep-sequencing readout, we analyzed hundreds of mutations under multiple drug conditions and found that the effects of mutations on growth in the presence or absence of drug were critical for predicting clinically relevant resistant mutations, many of which were cancer adaptive in the absence of drug pressure. Using this approach, we identified all clinically isolated BCR-ABL1 mutations and achieved a prediction score that correlated highly with their clinical prevalence. The strategy described here can be broadly applied to a variety of oncogenes to predict patient mutations and evaluate resistance susceptibility in the development of new therapeutics.
Keywords
BCR-ABL, CRISPR-Cas9–based genome editing, drug resistance, saturated mutagenesis, tyrosine kinase inhibitors
DOI of Published Version
10.1073/pnas.1708268114
Source
Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11751-11756. doi: 10.1073/pnas.1708268114. Epub 2017 Oct 16. Link to article on publisher's site
Journal/Book/Conference Title
Proceedings of the National Academy of Sciences of the United States of America
Related Resources
PubMed ID
29078326
Repository Citation
Ma L, Boucher JI, Paulsen JL, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu L(, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN. (2017). CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Schiffer Lab Publications. https://doi.org/10.1073/pnas.1708268114. Retrieved from https://escholarship.umassmed.edu/schiffer/20